The globalization of clinical trials in pulmonary arterial hypertension

Journal of Heart and Lung Transplantation

Volumn 29, Issue 2, 2010, Pages 157-158

  Park, Myung H ^a   Rubin, Lewis J ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; PROSTACYCLIN;

CLINICAL RESEARCH; CLINICAL TRIAL; DEVELOPING COUNTRY; EDITORIAL; HUMAN; MEDICAL LITERATURE; PHARMACOGENETICS; PRIORITY JOURNAL; PUBLICATION; PULMONARY HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; SULFONAMIDES; TREATMENT OUTCOME;

EID: 74849085481     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.11.605     Document Type: Editorial

References (9)

1. Hiremath J., Thanikachalam S., Parikh K., et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled study. J Heart Lung Transplant 29 (2010) 137-149
2. Jing Z.C., Strange G., Zhu X.Y., et al. An open-label, multi-center study to assess the efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension (PAH). J Heart Lung Transplant 29 (2010) 150-156
3. Gomberg-Maitland M. Traditional and alternative designs for pulmonary arterial hypertension trials. Proc Am Thorac Soc 5 (2008) 610-616
4. Halpern S.D., Doyle R., and Kawut S.M. The ethics of randomized clinical trials in pulmonary arterial hypertension. Proc Am Thorac Soc 5 (2008) 631-635
5. Frost A.E., McLaughlin V.V., Oudiz R.J., et al. Step-open label extension: long-term benefits of inhaled iloprost (ILO) addition to bosentan for treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med 175 (2007) A1001
6. Tufts Center for the Study of Drug Development. http://csdd/tufts.edu/Info.Services/Outlook Accessed: Nov 27, 2009
7. Thatte U.M., and Bavdekar S.B. Clinical trials in India: Great expectations?. J Postgrad Med 54 (2008) 318-323
8. Mehdiratta R., Parida D.K., and Saberwal G. Bio-business in brief: The challenges in clinical trials. Curr Sci 97 (2007) 1367-1375
9. Jin S.K., Chung H.J., Chung M.W., et al. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. J Clin Pharm Ther 33 (2008) 567-573